Composite outcomes in 2.25-mm drug eluting stents: a systematic review

Lee, Justin Z.; Singh, Nirmal; Ortega, Gilbert; Low, See Wei; Kanakadandi, Uday; Fortuin, F. David; Lassar, Tom; Lee, Kwan S.

doi:10.1016/j.carrev.2015.03.008

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Technological development led to the introduction of 2.0 mm stents in order to accommodate for smaller vessel size, but the clinical benefit of small stent implantation (≤ 2.25 mm) is vague [55]. The new portfolio of 2.0 mm DES (everolimus-eluting Xience Xpedition SV or Xience Alpine; zotarolimus-eluting Resolute Onyx) created new options of PCI in a smaller vascular territory, with promising results in retrospective analysis [55,56].…”

Section: Bms and Desmentioning

confidence: 99%

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

et al. 2021

View full text Add to dashboard Cite

The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery disease, which is related with higher rates of peri-and post-procedural complications and impaired long-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. Recent randomized controlled trials have provided new data on possible novel interventional treatment of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting stent implantation. Also, the conservative management represents a therapeutic option in light of the results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate definition, interventional management, and prognosis of small coronary artery atherosclerosis.

show abstract

Section: Bms and Desmentioning

confidence: 99%

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the TAXUS ATLAS (TAXUS Liberté-SR Stent for the Treatment of De Novo Coronary Artery Lesions) small vessel study, a thin-strut PES (97 mm) reduced the rate of 9-month angiographic restenosis and 12-month TLR compared with a thicker strut PES (132 mm)(46). Moreover, the availability of new generation DES with 2.25-and 2.00-mm diameters may further improve the feasibility and performance of coronary stenting in small vessels(47). Finally, new generation DESs have been associated with an improved safety and efficacy profile compared to early generation DES and DCB in different settings(41,48).Another finding of this network meta-analysis is that the use of BA for the treatment of small vessels should be avoided as this treatment resulted in the lowest ranking for all study outcomes.…”

mentioning

confidence: 99%